Breast Cancer

Researchers tested whether the GnRH antagonist degarelix was better at achieving and maintaining ovarian function suppression than the commonly used GnRH agonist triptorelin in premenopausal women with breast cancer.

Data from the Women’s Health Initiative showed that higher levels of body fat were associated with an increased risk of invasive breast cancer, calling into question BMI as an adequate marker for increased risk.

Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.

Dr. Susan Domchek discusses the increased understanding of moderate penetrance genes and the importance of managing patients with these genes on a case-by-case basis.

Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.

In this video, Dr. Allison Kurian discusses polygenic risk scores, genetic testing in diverse populations, and more as they relate to breast cancer.

In looking to improve quality of life, researchers studied whether partial breast irradiation was just as effective as whole breast irradiation.

The AMAROS trial tested RT to the axillary lymph node against ALND to see if some of the morbidity associated with surgery for breast cancer could be avoided.

Unilateral or bilateral mastectomy can have a significant effect on quality of life when compared with breast-conserving surgery in young breast cancer survivors.

In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity?

A study of a lifestyle intervention looked for improvement in disease-free or overall survival in early breast cancer patients.

The TAM01 trial looked at whether a 5-mg/day dose of tamoxifen was effective in patients with breast intraepithelial neoplasia, or if the 20-mg/day dose was still the best option.

A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer.

In this article, we describe the role of bone-targeted therapies, specifically for managing early breast cancer, by reviewing their bone-specific and cancer-specific benefits.

The combo showed improvement in disease-free survival over tamoxifen in premenopausal patients with hormone receptor (HR)-positive early breast cancer.

In this video, Dr. Minetta Liu outlines current research into profiling breast cancer cell-free DNA in the blood, potentially to identify clinically aggressive breast cancer subtypes.

In this video, Dr. Nancy Davidson highlights current and next-generation diagnostics and therapies in breast cancer, as well as the need for “team science” in clinical trials.

Researchers compared the cost effectiveness of two durations of trastuzumab in HER2+ breast cancer patients.

The SOLAR-1 trial tested whether the PI3K inhibitor alpelisib improved outcomes in HR+, HER2− breast cancer patients.

Dr. Adam Brufsky speaks with Cancer Network about the evolution and future of HER2-targeted therapy.

A subgroup analysis of Short-HER looked at the differences in 5-year DFS rates for 9 weeks vs 1 year of trastuzumab for HER2+ breast cancer patients.

Research presented this week at ESMO studied the efficacy of biosimilars to trastuzumab compared with the reference product in breast cancer.

Researchers tested whether combining chemotherapy with immunotherapy would offer improved survival for patients with triple-negative breast cancer.

In this study, researchers evaluated changes in CVD risk factors and 10-year CVD risk from before to after a breast cancer diagnosis, and compared it with women who remained free of such a diagnosis.

While becoming pregnant is generally possible for younger breast cancer patients, researchers believe many women change their minds after treatment.

In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy.

This article discusses the advances in HER2-targeted therapy, in both the metastatic and adjuvant settings, with a focus on those with early-stage breast cancer.

An otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?

Dr. Sparano discusses the implications of TAILORx, the first trial to use Oncotype DX in clinical decision making.

In a first-of-its-kind study, researchers analyzed how Twitter users talk about breast cancer on the social media platform.